Related references
Note: Only part of the references are listed.Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies
Murry W. Wynes et al.
CLINICAL CANCER RESEARCH (2014)
Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II study
K. Govind Babu et al.
ONCOTARGETS AND THERAPY (2014)
Tumor-Specific Cytotoxic T Cells Are Crucial for Efficacy of Immunomodulatory Antibodies in Patients with Lung Cancer
Joachim G. Aerts et al.
CANCER RESEARCH (2013)
Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non-Small Cell Lung Cancer
Stephanie Cardarella et al.
CLINICAL CANCER RESEARCH (2013)
Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the Lung
Jennifer M. Boland et al.
CLINICAL LUNG CANCER (2013)
Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non-Small-Cell Lung Cancer SWOG S0536
Edward S. Kim et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Epidermal Growth Factor Receptor Inhibition in Lung Cancer Status 2012
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
Marina Chiara Garassino et al.
LANCET ONCOLOGY (2013)
A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC)
Se Hyun Kim et al.
LUNG CANCER (2013)
Personalized therapy on the horizon for squamous cell carcinoma of the lung
Han Sang Kim et al.
LUNG CANCER (2013)
Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapy
Masami Ito et al.
BMC CANCER (2012)
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
Thomas J. Lynch et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial
Mark A. Socinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung Cancer
Rafal Dziadziuszko et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
James Chih-Hsin Yang et al.
LANCET ONCOLOGY (2012)
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
Robert Pirker et al.
LANCET ONCOLOGY (2012)
Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy
Alexander Drilon et al.
LANCET ONCOLOGY (2012)
Comprehensive genomic characterization of squamous cell lung cancers
Peter S. Hammerman et al.
NATURE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
J. Tanizaki et al.
BRITISH JOURNAL OF CANCER (2011)
Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations
Paul K. Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens
Natasha Rekhtman et al.
MODERN PATHOLOGY (2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
Amit Dutt et al.
PLOS ONE (2011)
Pathological Diagnosis and Classification of Lung Cancer in Small Biopsies and Cytology: Strategic Management of Tissue for Molecular Testing
William D. Travis et al.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Mutations in the DDR2 Kinase Gene identify a Novel therapeutic target in squamous cell lung cancer
Peter S. Hammerman et al.
CANCER DISCOVERY (2011)
Phase II Selection Design Trial of Concurrent Chemotherapy and Cetuximab Versus Chemotherapy Followed by Cetuximab in Advanced-Stage Non-Small-Cell Lung Cancer: Southwest Oncology Group Study S0342
Roy S. Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
Raga Krishnakumar et al.
MOLECULAR CELL (2010)
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Federico Cappuzzo et al.
LANCET ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
Jonathan Weiss et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Amplification of chromosomal segment 4q12 in non-small cell lung cancer
Alex H. Ramos et al.
CANCER BIOLOGY & THERAPY (2009)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker et al.
LANCET (2009)
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas
Adam J. Bass et al.
NATURE GENETICS (2009)
Targeting the phosphoinositide 3-kinase pathway in cancer
Pixu Liu et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung
Donatella Malanga et al.
CELL CYCLE (2008)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
Giorgio Vittorio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II Study of Celecoxib and Docetaxel in Non-small Cell Lung Cancer (NSCLC) Patients with Progression after Platinum-Based Therapy
Bryan J. Schneider et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy
Tatsuhiro Shibata et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
PIK3CA mutation and amplification in human lung cancer
Koji Okudela et al.
PATHOLOGY INTERNATIONAL (2007)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients
D Masuya et al.
BRITISH JOURNAL OF CANCER (2004)
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
DH Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Epidermal growth factor receptor in non-small-cell lung carcinomas:: Correlation between gene copy number and protein expression and impact on prognosis
FR Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung
K Funai et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2003)
Share Paper
